top
Search terms
Results 1 - 5 of 5 - ordered by :
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Anne E. de Leeuw, Rudolf A. de Boer

Date : 01/10/2016 Item size : 586778 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Anne E. de Leeuw, Rudolf A. de Boer

Date : 18/04/2016 Item size : 590679 bytes
Ehjcvp

The decreased risk of AF remained significant after adjusting for age, sex, and comorbidities with a hazard ratio (95% CI) of 0.76 (0.571.00), P0.047 associated with TZD treatment compared with other ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Jannik Langtved Pallisgaard, Tommi Bo Lindhardt, Laila Staerk, Jonas Bjerring Olesen, Christian Torp-Pedersen, Morten Lock ...

Date : 08/11/2016 Item size : 223886 bytes
Ehjcvp

[...]year of a journal Since they are selected due to their known knowledge and good reputation, my friends expected that their fees would be sky high. Laura Fortuna and co-workers from USA ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Stefan Agewall

Date : 01/01/2016 Item size : 108210 bytes
Ehjcvp

In recent years, guidance from both the US Food and Drug Administration (FDA)2 and the European Medicines Agency (EMA)3 addressing evaluation of the cardiovascular risk of new antidiabetic drugs for ...

European Heart Journal - Cardiovascular Pharmacotherapy, Editorials, J. Rick Turner, Dilip R. Karnad, Snehal Kothari, Alan Metz, Hitesh Patel, Erica Caveney

Date : 01/01/2017 Item size : 128050 bytes